Skip to Main content Skip to Navigation
Journal articles

Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study

Sophie Vantyghem 1 Pierre Peterlin 1 Sylvain Thépot 2, 3 Audrey Ménard 4 Viviane Dubruille 1 Camille Debord 4 Thierry Guillaume 1 Alice Garnier 1 Amandine Le Bourgeois 1 Soraya Wuilleme 4 Catherine Godon 4 Olivier Theisen 4 Marion Eveillard 5, 4 Jacques Delaunay 6 Hervé Maisonneuve 7 Nadine Morineau 7 Bruno Villemagne 7 Stéphane Vigouroux 7 François Subiger 8 Elsa Lestang 9 Marion Loirat 9 Anne Parcelier 10 Pascal Godmer 10 Mélanie Mercier 10 Adrien Trebouet 11 Damien Luque Paz 2, 12 Ronan Le Calloch 13 Lenaïg Le Clech 13 Céline Bossard 14 Anne Moreau 14 Valérie Ugo 2, 12 Mathilde Hunault 2, 3 Philippe Moreau 15, 16 Steven Le Gouill 5, 16 Patrice Chevallier 17, 16 Marie C Béné 17, 4 yannick Le Bris 5, 4 
Abstract : Next generation sequencing (NGS) investigates for somatic mutations. The utility of incorporating routine sequencing to guide diagnosis and therapeutic decisions remains challenging. We report an observational multicentric study that aimed to assess the impact of somatic mutations testing by NGS in a real-life setting of chronic myeloid malignancies (CMM). A total of 177 patients were enrolled, partitioned in two overlapping groups. In group A (N=94), the indication was to search for clonal hematopoiesis (CH), in a context of suspected myelodysplastic syndrome or myeloproliferative neoplasia. In group B (N=95), the theranostic impact of somatic mutations was studied. A panel of 34 genes was applied on DNA extracted from blood or bone marrow samples. Within group A, the detection of CH comforted the diagnosis of CMM for 31 patients while absence of CH ruled out the suspected diagnosis in 47 patients. Within group B, NGS identified prognostic somatic mutations in 32 patients, with a therapeutic impact in 18 cases. The use of NGS in daily practice was found here to be useful for an integrated final diagnosis in 83% of the patients through the presence or absence of somatic mutations. Moreover, exploration for somatic mutations had a prognostic impact that led to treatment modification in 19% of the cases. This study outlines the fact that adequate prescription of these new investigations may have a significant positive medico-economic impact by allowing appropriate management of the patients.
Document type :
Journal articles
Complete list of metadata
Contributor : Elizabeth Bernardo Connect in order to contact the contributor
Submitted on : Thursday, April 23, 2020 - 12:06:53 PM
Last modification on : Wednesday, May 25, 2022 - 4:22:09 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Sophie Vantyghem, Pierre Peterlin, Sylvain Thépot, Audrey Ménard, Viviane Dubruille, et al.. Diagnosis and prognosis are comforted by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. Haematologica, Ferrata Storti Foundation, 2021, 106 (3), pp.701-707. ⟨10.3324/haematol.2019.242677⟩. ⟨inserm-02552097⟩



Record views